Infrastructure FOr Rare Cancer in the NEtherlands, towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE), and especially neuroendocrine neoplasms (NEN)

#3963

Introduction: NEN consist of a heterogeneous group of rare tumors. For these patients, clinical trials requiring a high number of patients are often infeasible. Often, the prognosis is poor due to late diagnosis and fewer available treatment options as compared to patients with common cancer types. In common cancers, ultrasensitive molecular profiling of circulating cell-free DNA (USccfDNA) based tests are promising to improve diagnosis, detection of minimal residual disease (MRD), and recurrence. Data needed to apply USccfDNA in NEN is lacking.

Aim(s): FORCE-NEN aims to ultimately improve treatment outcomes for patients with rare cancers by facilitating research through systematic collection of clinical data, and peripheral blood components.

Materials and methods: In FORCE retrospectively and prospectively collected data are used to build a data warehouse that provides insight into the long-term biology of a rare cancer. Blood samples for detection of USccfDNA are collected according to standard operating procedures.

Conference:

Presenting Author:

Authors: de Hosson L, Pieterman C, Fehrmann R, de Herder W, Jalving M,

Keywords: circulating cell free DNA, biobank, databank, early detection,